Linnea Olson: An Appreciation of a Giant (Preprint)

2022 ◽  
Author(s):  
John Novack
Keyword(s):  
Clinical Trials ◽  
Cancer Patient ◽  
Cancer Clinical Trials ◽  
Patient Advocate

UNSTRUCTURED Reviewing the life and impact of the late Linnea Olson, a cancer patient advocate who helped shape cancer clinical trials

The Coalition of cancer cooperative groups GI scientific leadership council

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13522-13522
Author(s):  
R. B. Catalano ◽  
R. L. Comis ◽  
M. J. O’Connell
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Pharmaceutical Industry ◽  
Research Priorities ◽  
Science Research ◽  
The United States ◽  
Advisory Group ◽  
Cancer Clinical Trials ◽  
Cooperative Groups ◽  
Patient Advocate

13522 Background: The Coalition of Cancer Cooperative Groups convened the GI Scientific Leadership Council (GI SLC) to provide leadership in establishing and advancing national research priorities for colorectal cancer clinical trials. A key objective was to complement and enhance the scientific programs of the NCI-sponsored GI Intergroup. Methods: A multidisciplinary group of investigators representing the spectrum of diagnostic, therapeutic, and laboratory disciplines engaged in colorectal cancer clinical research was convened in December 2004 to address the most important research opportunities in colorectal cancer, and clinical trials to address those opportunities. In April 2005, the concepts evolved were discussed with representatives of the patient advocate community and the pharmaceutical industry. In December 2005 the GI SLC presented its core research recommendations to more than 100 members of the cancer community. Results: Seven principal cross-cutting themes emerged, as well as ten strategic recommendations to be addressed over the next three years. A portfolio of high priority clinical trials was identified. The GI SLC has prioritized support for three colon cancer surgical adjuvant trials; two rectal cancer surgical adjuvant trials; two colorectal cancer metastatic to the liver trials; two metastatic colorectal trials; and one colon polyp and cancer detection study trial. These will be detailed in our presentation. Conclusions:The GI Scientific Leadership Council represents a novel approach to strengthen colorectal cancer clinical trials and correlative science research in the United States by providing a platform to bring together clinical investigators and translational researchers, the patient advocate community, and the pharmaceutical industry. The GI SLC plans to convene a Cancer Prevention Advisory Group in the first quarter of 2006 and plans to initiate one or more innovative clinical trials in collaboration with industry in 2006. The GI SLC will meet throughout 2006 to develop action plans, review progress towards those plans, and facilitate adoption of the research priorities across the cancer community. No significant financial relationships to disclose.

scholarly journals Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Leona M. Batten ◽  
Indrani Subarna Bhattacharya ◽  
Laura Moretti ◽  
Joanne S. Haviland ◽  
Marie A. Emson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Cancer Clinical Trials ◽  
Patient Advocate ◽  
Multiple Biopsies

Assessing the effect of toxicity on prognosis: methods of analysis and interpretation.

1988 ◽  
Vol 6 (5) ◽  
pp. 868-870 ◽  
Author(s):  
K J Propert ◽  
J R Anderson
Keyword(s):  
Clinical Trials ◽  
Treatment Outcome ◽  
Cancer Patient ◽  
Time Dependence ◽  
Statistical Analyses ◽  
Cytotoxic Agents ◽  
Cancer Clinical Trials ◽  
Time To Failure ◽  
Statistical Methodology ◽  
The Individual

There has recently been an increased interest in and reporting of the association between toxicity and treatment outcome in cancer clinical trials. Such comparisons may be used to suggest mechanisms by which cytotoxic agents function in the cancer patient, especially regarding the importance of the effect of dose on the individual patient. However, analyses of "time-to-failure" outcomes such as survival by toxicity are subject to bias due to the time-dependence of both the predictor and outcome variables. In addition, interpretation of even appropriately conducted statistical analyses is problematic, as with analyses of survival by outcome variables such as response. The use of statistical methodology designed to avoid such biases in these comparisons is shown and the problems in the interpretation of results are discussed.

Signaling inhibition with radiation in colorectal cancer: Clinical trials

2003 ◽  
Vol 30 (3 Suppl 6) ◽  
pp. 56-67 ◽  
Author(s):  
W. Gillies McKenna ◽  
Ruth J. Muschel ◽  
Anjali Gupta ◽  
Stephen Hahn ◽  
Eric J. Bernhard
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Cancer Clinical Trials

Targeting Metabolic Enzymes in Cancer – Clinical Trials Update

2013 ◽  
Vol 9 (2) ◽  
pp. 152-160
Author(s):  
Julie O’Neal ◽  
Jason Chesney
Keyword(s):  
Clinical Trials ◽  
Metabolic Enzymes ◽  
Cancer Clinical Trials

scholarly journals Publication Rate and Characteristics of Lung Cancer Clinical Trials

2019 ◽  
Vol 2 (11) ◽  
pp. e1914531
Author(s):  
Ghassan Al-Shbool ◽  
Hira Latif ◽  
Saira Farid ◽  
Shuqi Wang ◽  
Jaeil Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Publication Rate ◽  
Cancer Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document